IPO Trending
WINDLASEQ / NSE, BSEListed

Windlas Biotech Limited

Incorporated in 2001, Windlas Biotech Ltd is a prominent pharmaceutical company in India’s CDMO segment, offering end-to-end services from product discovery and development to licensing and commercial manufacturing of generic and complex generic products. The company also markets its own branded products in the trade generics and OTC segments, focusing on chronic therapeutic categories related to lifestyle disorders. Windlas Biotech operates across three verticals: CDMO services, domestic trade generics and nutraceuticals, and exports. Its marquee clients include Pfizer, Sanofi India, Cadila Healthcare, Emcure Pharmaceuticals, Eris Lifesciences, Intas Pharmaceuticals, and Systopic Laboratories. The company’s Dehradun-based manufacturing facilities have an installed capacity of 7,063.83 million tablets/capsules, 54.46 million pouches/sachets, and 61.08 million liquid bottles.

₹448 - ₹460Open
Listed Price437.00
Listing Gain-5.00%
FinancialsBalance sheet and operational figures in Crores
Metric Breakdown

Revenue

Latest (Mar-21)4306.95 Cr
Growth+38.3%
Revenue Trend (₹ in Crores)
0.01.7k3.3k5.0kMar-19Mar-20Mar-21
PeriodRev (Cr)PAT (Cr)AssetsDebt
Mar-214,306.95155.702,961.230
Mar-203,313.39162.133,384.880
Mar-193,115.25638.222,981.800
Windlas Biotech Limited IPO Financials | GMP, Allotment & Financials | IPO Trending